Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.
We grade stocks based on past performance, their future growth potential, intrinsic value, dividend history, and overall financial health.
The chart below shows how we grade Akari Therapeutics (AKTX) across the board compared to its closest peers.
Benzinga Edge stock rankings give you four critical scores to help you identify the strongest and weakest stocks to buy and sell.
1.9
Momentum measures a stock's relative strength based on its price movement patterns and volatility over multiple timeframes, ranked as a percentile against other stocks.
See how Akari Therapeutics compares to its peers in these key performance metrics from Benzinga Rankings.
The two main factors that we consider when analyzing past performance is overall return and volatility
Using these two metrics, we can determine if this stock gave its investors enough return for the risk that they took on by owning it. This is measured by the sharpe ratio, which has been used as a primary measure of risk/reward trade-off for almost 60 years.
This ratio can be interpreted as the amount of return an investor has received for the amount of risk that they took on by owning the stock over that timeframe.
Akari Therapeutics (AKTX) sharpe ratio over the past 5 years is -0.0312 which is considered to be above average compared to the peer average of -0.0313